A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation.

Charity G Duran, Allison J Burbank, Katherine H Mills, Heather R Duckworth, Maria M Aleman, Matthew J Kesic, David B Peden, Yinghao Pan, Haibo Zhou, Michelle L Hernandez

Journal: Respiratory research 2017;17(1):89

PMID: 27450419

Abstract

UNLABELLED

Sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, is implicated as a possible therapy for airway inflammation via induction of the transcription factor NF-E2-related factor 2 (NRF2). In this proof-of-concept clinical study, we show that supplementation of SFN with broccoli sprout homogenate in healthy human subjects did not induce expression of antioxidant genes or protect against neutrophilic airway inflammation in an ozone-exposure model. Therefore, dietary sulforaphane supplementation is not a promising candidate for larger scale clinical trials targeting airway inflammation.

TRIAL REGISTRATION

NCT01625130 . Registered 19 June, 2012.

Address: UNC Center for Environmental Medicine, Asthma, & Lung Biology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Physical Therapy, Methodist University, Fayetteville, NC, USA.; Department of Biostatistics, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; UNC Center for Environmental Medicine, Asthma, & Lung Biology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. [email protected].; Division of Allergy, Immunology & Rheumatology, UNC School of Medicine, 104 Mason Farm Road, CB #7310, Chapel Hill, NC, 27599-7310, USA. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.